{"disease":{"id":"excessive-sleepiness","name":"excessive sleepiness"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06898008","title":"Characterization of Children with Complaints of Excessive Daytime Sleepiness","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03194217","title":"BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"BenevolentAI Bio","has_results":true},{"nct_id":"NCT05223166","title":"A Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of EDS in Patients With OSA","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Citrine Medicine Limited","has_results":false},{"nct_id":"NCT02720744","title":"Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":212,"lead_sponsor_name":"Avadel","has_results":true},{"nct_id":"NCT07082829","title":"A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"Centessa Pharmaceuticals (UK) Limited","has_results":false},{"nct_id":"NCT06103825","title":"A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Ignis Therapeutics (Suzhou) Limited","has_results":false},{"nct_id":"NCT05458128","title":"A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Harmony Biosciences Management, Inc.","has_results":false},{"nct_id":"NCT05822128","title":"Alternative Epworth Sleepiness Scale ESS-ALT in French","phase":"","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05059223","title":"A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Axsome Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04788953","title":"Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":84,"lead_sponsor_name":"Charles A. Czeisler, PhD, MD","has_results":true},{"nct_id":"NCT05113745","title":"A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Axsome Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04923594","title":"Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"NLS Pharmaceutics","has_results":false},{"nct_id":"NCT04789174","title":"Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Axsome Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06872593","title":"Validating a Novel Driving Simulation-based MWT Against the Standard MWT in an OSA-cohort Challenged by CPAP-withdrawal","phase":"NA","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Stefan Lakämper","has_results":false},{"nct_id":"NCT02806895","title":"Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT04886518","title":"Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Harmony Biosciences Management, Inc.","has_results":true},{"nct_id":"NCT03881852","title":"Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Axsome Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04618263","title":"Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"Syndeio Biosciences, Inc","has_results":false},{"nct_id":"NCT06711159","title":"SLEEPINESS - a Search for a Biomarker of Excessive Daytime Sleepiness in Severe Obstructive Sleep Apnoea - An Explorative Study","phase":"","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Zealand University Hospital","has_results":false},{"nct_id":"NCT05008341","title":"Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Axsome Therapeutics, Inc.","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}